Antisense reports loss in lead-up to MS trial

By Tanya Hollis
Friday, 15 March, 2002

Australia's newest listed biotechnology company, Antisense Therapeutics (ASX:ANP), today recorded a first-half loss of $1.6 million as it prepares for a pre-clinical study of its multiple sclerosis therapy.

Antisense also told the market it was company policy to expense all research and development costs, another contributor to the interim loss.

The Melbourne company listed on the Australian Stock Exchange on December 20, raising $13 million in its public offering and putting its market capitalisation at $59 million as at December 31.

Its work involves antisense drugs, intended to enter cells and block the protein-producing activity of specific genes rather than the proteins themselves and therefore acting at an earlier stage of disease than conventional therapies.

Its most advanced projects are currently its ATL1102 multiple sclerosis project, done in collaboration with US company Isis Pharmaceuticals, and its ATL1101 psoriasis therapy, which is being developed in conjunction with the Murdoch Children's Research Institute.

In its statement to the market today, the company said $1.1 million of its declared loss related to the supply by Isis of the active drug substance to be used for pre-clinical toxicology studies of its lead multiple sclerosis agent.

Antisense also revealed a humble $21,000 in revenue for the past six months.

Related News

Protein-based therapy helps the body remove harmful cells

Scientists have created a protein-based therapeutic tool that could change the way we treat...

Diabetes changes the structure of our hearts, study finds

Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...

Beta blockers could halt triple negative breast cancer

Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd